<DOC>
	<DOCNO>NCT02189837</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled trial evaluate effect evolocumab , atorvastatin , combination therapy lipoprotein kinetics .</brief_summary>
	<brief_title>Effects Lipoprotein Metabolism From PCSK9 Inhibition Utilizing Monoclonal Antibody</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Fasting LDLC screen ≥ 100 mg/dL ≤ 190 mg/dL Fasting triglycerides ≤ 150 mg/dL Body mass index ( BMI ) 18.0 32.0 kg/m^2 Framingham cardiac risk score 10 % le Treatment lipidregulating drug counter supplement last 3 month prior screen History coronary heart disease ( CHD ) CHD equivalent Uncontrolled hypertension Diabetes mellitus</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Raised cholesterol</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>Elevated Cholesterol</keyword>
	<keyword>Hyperlipidemias</keyword>
	<keyword>Dyslipidemias</keyword>
	<keyword>Lipid Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
</DOC>